FDA Purple Book · Reference family
ocriplasmin (Jetrea)
ocriplasmin is an FDA-licensed reference biologic from ThromboGenics Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2012
Reference approved
Reference product
351(a)BLA 125422
Jetrea ocriplasmin
ThromboGenics Inc.
- Approved
- Oct 17, 2012
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for ocriplasmin, in chronological order.
Reference approval
Approval date of the reference ocriplasmin product.
13 yr 10 mo ago
Frequently asked questions
Are there biosimilars approved for ocriplasmin (Jetrea)?
No 351(k) biosimilars or interchangeable biosimilars referencing ocriplasmin are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.